OncoSil Medical (ASX: OSL) has been awarded a key U.S. patent covering its OncoSil™ nuclear medical device that is being developed for treatment of locally advanced pancreatic cancer.
The company plans to initiate a pivotal study for the device in the first quarter of 2014 that would enrol 100-300 patients.
Interest in the device is high as highlighted by the strong response to the company’s oversubscribed placement that raised $7.8 million.
Patent 13/314,239, titled “Devices and Methods for the Treatment of Cancer” was awarded by the US Patent and Trademark Office and extends to 2022.
OncoSil™ is an active implantable medical device that provides a localised radiation therapy for tumours, avoiding the systemic side effects of external radiation treatment.
OncoSil™ has already two successful Phase II studies under Enigma Therapeutics, which OncoSil acquired in April this year.
Analysis of patients in the first pilot trial had demonstrated significant tumouricial (cancer cell destroying) activity with a disease control rate of 82% along with a reduction in pain.
A second study confirmed the 400Gy radiation dose was well tolerated and that no adverse events with the device occurred. This also demonstrated a tumour control rate was 100%, and confirmed stabilisation of tumour growth but was stopped at an early stage due to a change in focus by the previous owner.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.